LONDON, May 11, 2017 /PRNewswire/ --
Despite a strong run over the last 12 months, our increased valuation of $2.7bn suggests the market overlooks HCM's full R&D potential. Multiple catalysts are on the horizon in 2017/18; notably the China FDA filing for fruquintinib in CRC (full Phase III CRC data [China] at ASCO) and overall survival data from the savolitinib Phase II trial in c-Met-driven PRCC (could support a US NDA submission). Further progress of the early to mid-stage pipeline over time should retain investors focus. Ultimately, HCM's move to commercialise its innovative pipeline in its domestic market (and longer term in international territories) could provide a major source of uplift.